This is the authors' abstract. We don't add key points for this paper.
Withdrawing Approval of Makena The FDA’s Center for Drug Evaluation and Research has recommended withdrawing the approval of Makena for the prevention of recurrent preterm birth after a trial faile...
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Chang et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: